STERIS (NYSE:STE) VP John Adam Zangerle Sells 1,419 Shares

STERIS plc (NYSE:STE) VP John Adam Zangerle sold 1,419 shares of the business’s stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $209.28, for a total transaction of $296,968.32. Following the sale, the vice president directly owned 35,259 shares of the company’s stock, valued at approximately $7,379,003.52. This represents a 3.87% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

STERIS Price Performance

Shares of NYSE:STE opened at $206.64 on Wednesday. The company has a quick ratio of 1.54, a current ratio of 2.09 and a debt-to-equity ratio of 0.25. STERIS plc has a fifty-two week low of $195.14 and a fifty-two week high of $269.44. The firm has a 50-day simple moving average of $215.59 and a 200 day simple moving average of $236.34. The company has a market cap of $20.14 billion, a PE ratio of 26.06 and a beta of 0.93.

STERIS (NYSE:STE) last posted its earnings results on Monday, May 11th. The medical equipment provider reported $2.83 EPS for the quarter, missing the consensus estimate of $2.86 by ($0.03). STERIS had a return on equity of 14.15% and a net margin of 13.18%.The firm had revenue of $1.59 billion during the quarter, compared to the consensus estimate of $1.59 billion. During the same quarter last year, the company posted $2.74 EPS. STERIS’s revenue for the quarter was up 6.7% on a year-over-year basis. STERIS has set its FY 2027 guidance at 11.100-11.300 EPS. On average, sell-side analysts anticipate that STERIS plc will post 11.18 EPS for the current year.

STERIS Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, June 26th. Stockholders of record on Monday, June 8th will be paid a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a dividend yield of 1.2%. The ex-dividend date of this dividend is Monday, June 8th. STERIS’s dividend payout ratio is currently 31.78%.

Institutional Trading of STERIS

Large investors have recently modified their holdings of the company. Jones Financial Companies Lllp boosted its holdings in STERIS by 46.1% in the 1st quarter. Jones Financial Companies Lllp now owns 1,106 shares of the medical equipment provider’s stock valued at $251,000 after purchasing an additional 349 shares during the period. Goldman Sachs Group Inc. boosted its holdings in STERIS by 32.3% in the 1st quarter. Goldman Sachs Group Inc. now owns 242,732 shares of the medical equipment provider’s stock valued at $55,015,000 after purchasing an additional 59,264 shares during the period. Empowered Funds LLC boosted its holdings in STERIS by 16.1% in the 1st quarter. Empowered Funds LLC now owns 2,303 shares of the medical equipment provider’s stock valued at $522,000 after purchasing an additional 319 shares during the period. Woodline Partners LP boosted its holdings in STERIS by 40.0% in the 1st quarter. Woodline Partners LP now owns 8,300 shares of the medical equipment provider’s stock valued at $1,881,000 after purchasing an additional 2,372 shares during the period. Finally, Jane Street Group LLC boosted its holdings in STERIS by 38.9% in the 1st quarter. Jane Street Group LLC now owns 20,716 shares of the medical equipment provider’s stock valued at $4,695,000 after purchasing an additional 5,803 shares during the period. 94.69% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

STE has been the subject of several recent research reports. Piper Sandler reissued an “overweight” rating and set a $270.00 target price on shares of STERIS in a research note on Thursday, May 21st. Weiss Ratings lowered shares of STERIS from a “hold (c+)” rating to a “hold (c)” rating in a research note on Wednesday, May 27th. KeyCorp dropped their price objective on shares of STERIS from $291.00 to $269.00 and set an “overweight” rating on the stock in a research note on Wednesday, May 13th. Finally, Wall Street Zen lowered shares of STERIS from a “strong-buy” rating to a “buy” rating in a research note on Saturday, June 6th. Three analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat.com, STERIS has an average rating of “Moderate Buy” and a consensus price target of $278.00.

About STERIS

STERIS Corporation (NYSE: STE) is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.

Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.